Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telavancin for Gram-Positive Bacteremia in Cancer Patients
NCT01321879Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2011
- Primary completion
- Dec 2016
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of telavancin in Bacteremia, sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2011; status: completed.
02
Drugs
telavancin
03
Conditions
Bacteremia
Beyond the preview
Go deeper on NCT01321879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01321879.